Cargando…
Assessment and monitoring of biologic drug adverse events in patients with psoriasis
BACKGROUND: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events. OBJECTIVE: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the trea...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683127/ https://www.ncbi.nlm.nih.gov/pubmed/29387593 http://dx.doi.org/10.2147/PTT.S68869 |
_version_ | 1783278220885360640 |
---|---|
author | Hanley, Tessa Handford, Marc Lavery, Dawn Yiu, Zenas ZN |
author_facet | Hanley, Tessa Handford, Marc Lavery, Dawn Yiu, Zenas ZN |
author_sort | Hanley, Tessa |
collection | PubMed |
description | BACKGROUND: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events. OBJECTIVE: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events. METHODS: The MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab. LIMITATIONS: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy. RESULTS: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility. CONCLUSION: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies. |
format | Online Article Text |
id | pubmed-5683127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56831272018-01-31 Assessment and monitoring of biologic drug adverse events in patients with psoriasis Hanley, Tessa Handford, Marc Lavery, Dawn Yiu, Zenas ZN Psoriasis (Auckl) Review BACKGROUND: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events. OBJECTIVE: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events. METHODS: The MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab. LIMITATIONS: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy. RESULTS: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility. CONCLUSION: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies. Dove Medical Press 2016-04-01 /pmc/articles/PMC5683127/ /pubmed/29387593 http://dx.doi.org/10.2147/PTT.S68869 Text en © 2016 Hanley et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Hanley, Tessa Handford, Marc Lavery, Dawn Yiu, Zenas ZN Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title | Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title_full | Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title_fullStr | Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title_full_unstemmed | Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title_short | Assessment and monitoring of biologic drug adverse events in patients with psoriasis |
title_sort | assessment and monitoring of biologic drug adverse events in patients with psoriasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683127/ https://www.ncbi.nlm.nih.gov/pubmed/29387593 http://dx.doi.org/10.2147/PTT.S68869 |
work_keys_str_mv | AT hanleytessa assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT handfordmarc assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT laverydawn assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT yiuzenaszn assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis |